News and Trends 4 Jun 2019
Austrian Biotech Raises €19M to Commercialize First Chikungunya Vaccine
The market is in sight for the first potential vaccine for the chikungunya virus, as the company Themis Bioscience will receive up to €18.7M ($21M) in non-dilutive funding to finance the vaccine’s phase III development. The money will cover most of the costs of the phase III trial, which Themis expects to begin later this […]